Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients

Click here to see our Second Quarter 2019 Financial Results and Business Update

Adaptimmune announces start of SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS

You can find new videos about our SPEAR T-cells

Explore stories from our colleagues and external experts on our science and how we're working to improve patient lives by transforming cancer treatment

Focusing on the needs of our patients

Latest News • View all

Adaptimmune on Linkedin linkedin

Adaptimmune on Twitter